CSIMarket
 
Biocept Inc   (BIOC)
Other Ticker:  
 
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
 
Price: $0.4349 $-0.07 -13.055%
Day's High: $0.4901 Week Perf: -20.93 %
Day's Low: $ 0.40 30 Day Perf: -70.01 %
Volume (M): 751 52 Wk High: $ 13.43
Volume (M$): $ 327 52 Wk Avg: $1.18
Open: $0.49 52 Wk Low: $0.21



 Market Capitalization (Millions $) 0
 Shares Outstanding (Millions) 1
 Employees 135
 Revenues (TTM) (Millions $) -8
 Net Income (TTM) (Millions $) -39
 Cash Flow (TTM) (Millions $) -16
 Capital Exp. (TTM) (Millions $) 1

Biocept Inc
Biocept Inc is a publicly-traded molecular diagnostics company based in San Diego, California, which specializes in developing liquid biopsy tests to improve the detection and monitoring of various types of cancer.

The company was founded in 1997 and went public in 2014 on the NASDAQ stock exchange under the symbol "BIOC". Since then, Biocept has become a trusted leader in the field of liquid biopsy testing, allowing physicians to analyze circulating tumor cells (CTCs), cell-free DNA (cfDNA), and other cancer biomarkers in the bloodstream. This approach enables doctors to make more informed decisions about cancer diagnoses, treatment plans, and monitoring.

Biocept's proprietary technology platform is called Target Selector, which is designed to capture and analyze rare cells and fragments of cancer DNA circulating in patients' blood. The company's liquid biopsy tests are used to detect, diagnose, and monitor various types of cancer, including lung, breast, colorectal, gastric, prostate, and melanoma.

In addition to its liquid biopsy tests, Biocept also offers a variety of other biomarker assays, including tests for HER2, estrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR), and more. These assays help doctors to guide targeted cancer therapies and monitor patients' responses to treatment.

Biocept has partnerships with major healthcare providers worldwide, including Quest Diagnostics and the University of Texas MD Anderson Cancer Center. The company also works closely with pharmaceutical companies to develop companion diagnostic tests for their cancer drugs.

Overall, Biocept is committed to advancing the diagnosis and treatment of cancer through innovative liquid biopsy testing, cutting-edge technology, and strategic partnerships with healthcare providers and pharmaceutical companies. The company's mission is to improve patient outcomes and enhance the quality of life for those affected by cancer.


   Company Address: 9955 Mesa Rim Road San Diego 92121 CA
   Company Phone Number: 320-8200   Stock Exchange / Ticker: NASDAQ BIOC
   BIOC is expected to report next financial results on April 16, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Biocept Inc

Biocept Inc's Second Quarter 2023 Report Reveals Shocking -94.449% Drop in Revenue: a Critical Concern for the Medical Laboratories Sector

Biocept Inc (BIOC) has recently released its second-quarter financial report for 2023, and the results are disastrous. The company's revenue plummeted by a staggering -94.449% to a mere $0.59 million. This significant decline in revenue is alarming, especially when compared to the rest of the Medical Laboratories sector, which experienced revenue growth during the same period.
Furthermore, the company's shortfall per share has widened to $-3.50, a considerable deterioration from the previous year's reporting season. In comparison to the prior reporting season, revenue deteriorated sequentially by -12.481% from $0.67 million.

Biocept Inc

Biocept Inc's First Quarter 2023 Earnings Plunge by 96.6% - Shockwaves Hit Investors

Investors React to Biocept Inc's Disastrous First Quarter Earnings
Investors are reeling from the announcement of Biocept Inc's disastrous first quarter 2023 earnings. The medical laboratories company reported a staggering -96.626% decrease in revenue, falling to just $0.67 million from the corresponding reporting period of the previous year. Its net loss per share has also widened to $-0.41, sending shockwaves through the investment community.
The sudden downturn in Biocept Inc's financials has taken many investors by surprise. Sequentially, revenue turned positive from $-10.29 million, but this was not enough to offset the significant losses incurred over the January to March 31, 2023 timeframe. The company realized a net shortfall of $-7.144 million, far greater than the $-2.768 million from the same period a year ago.






 

Biocept Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com